Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bositao Controlled Release Pharmaceutical Co

Request full access

A high-tech enterprise with a new drug delivery system as its core

Guangzhou, ChinaFounded 2013Biotech & Life Sciences

About Bositao Controlled Release Pharmaceutical Co

Bositao Controlled Release Pharmaceutical Co., Ltd., also known as Bostal Drug Delivery, operates as a technology-focused pharmaceutical company specializing in drug delivery systems. Founded in 2013 by Dr. Ron Liu in Guangzhou, China, the company leverages the foundation of Bostal LLC (formerly AustarPharma), which Dr. Liu established in New Jersey, USA, in 2004. Dr. Liu, an expert in pharmaceutical formulation technologies with over 30 years of experience at firms like Pfizer, Abbott, and Bristol-Myers Squibb, leads the company as Chairman and CEO. His background includes authoring "Water-Insoluble Drug Formulation" and serving on the NIH's New Drug Release Technology review committee.

The company's business model is centered on providing a "one-stop" platform for drug development and commercialization for its clients, primarily international pharmaceutical companies. This integrated service encompasses formulation development, pharmacodynamics, toxicology, clinical studies, contract manufacturing, and registration. A significant milestone was the 2009 acquisition of an Abbott Laboratories cGMP commercial manufacturing facility in Edison, New Jersey, which now serves as the corporate headquarters and can produce two billion solid oral dosage units annually. The company has also established a major presence in Guangzhou with a 68,000 square meter International Pharmaceutical Park and passed inspections by both the US FDA and China's NMPA.

Bositao specializes in advanced drug delivery technologies, particularly for controlled-release and water-insoluble drugs. Its technology platforms include oral sustained/controlled release preparations, long-acting injectable microspheres, long-acting implants, osmotic pump systems, and solubilization techniques like hot melt extrusion and spray drying. The company develops and manufactures a range of complex formulations such as multi-layered matrix tablets, pellet-filled capsules, and injectable in-situ gels. Its own R&D pipeline focuses on treatments for major diseases including metabolic disorders, psychiatric conditions, and malignant tumors. Bositao also markets and distributes finished generic and specialty drug products in the U.S. through internal development and strategic partnerships.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Aug 2023 $28M $110M Guangdong Technology Financial Group · Chuangyu Investment · Yuecai Zhongyin ↗
SERIES BOther financing Apr 2022 $28M $110M Chuangyu Investment · Guangzhou Jet Biofiltration · Sanmei Investment · Huatai Zijin Investment ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Bositao Controlled Release Pharmaceutical Co website traffic

Latest recorded traffic for Bositao Controlled Release Pharmaceutical Co is 1.2K monthly website visits, up 0% over the last three months.

Latest monthly visits1.2K 3-month web change0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Bositao Controlled Release Pharmaceutical Co in the Guangzhou ecosystem

Live from Dealroom

The Bositao Controlled Release Pharmaceutical Co office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Chuangyu Investment
  • Guangzhou Jet Biofiltration
  • Sanmei Investment
  • Huatai Zijin Investment
  • Guangdong Technology Financial Group
  • Yuecai Zhongyin
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Guangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Bositao Controlled Release Pharmaceutical Co on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bositao Controlled Release Pharmaceutical Co’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.